Dissecting the role of ubiquitylation in the DNA damage response checkpoint in G2

Cell Death and Differentiation

Volumn 17, Issue 1, 2010, Pages 78-85

  Bassermann, F ^a   Pagano, M ^b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

cell cycle; checkpoint; DNA damage response; G2 phase; Ubiquitylation

Indexed keywords

PROTEASOME; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; ANAPHASE PROMOTING COMPLEX; ANAPHASE-PROMOTING COMPLEX; CYCLIN DEPENDENT KINASE 1;

APOPTOSIS; ASSAULT; CANCER RISK; CELL CYCLE G2 PHASE; DNA DAMAGE; DRUG DEVELOPMENT; DYNAMICS; EUKARYOTE; GENOME; GENOMIC INSTABILITY; GENOMICS; HOSPITAL SERVICE; HUMAN; MUTAGENIC ACTIVITY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; UBIQUITINATION; METABOLISM; PHYSIOLOGY;

EUKARYOTA;

CDC2 PROTEIN KINASE; DNA DAMAGE; G2 PHASE; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITINATION;

EID: 77449097602     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.104     Document Type: Review

References (80)

1. Bakkenist CJ, Kastan MB. Initiating cellular stress responses. Cell 2004; 118: 9-17. (Pubitemid 38902810)
2. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007; 28: 739-745. (Pubitemid 350217064)
3. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323. (Pubitemid 39551659)
4. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008; 9: 297-308. (Pubitemid 351430844)
5. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 2004; 3: 997-1007. (Pubitemid 38997942)
6. Hakem R. DNA-damage repair; the good, the bad, and the ugly. EMBO J 2008; 27: 589-605. (Pubitemid 351273123)
7. Kennedy RD, D'ndrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006; 24: 3799-3808. (Pubitemid 46622318)
8. Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50- Nbs1 complex. Science 2005; 308: 551-554. (Pubitemid 40570585)
9. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005; 434: 605-611. (Pubitemid 40488547)
10. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J et al. ATM- and cell cycledependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8: 37-45. (Pubitemid 43064795)
11. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 2007; 19: 238-245. (Pubitemid 46386406)
12. Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 2004; 5: 739-751. (Pubitemid 39208183)
13. Peters JM. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 2006; 7: 644-656.
14. Li M, Zhang P. The function of APC/CCdh1 in cell cycle and beyond. Cell Div 2009; 4: 2.
15. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449. (Pubitemid 351744963)
16. Bassermann F, von Klitzing C, Illert AL, Munch S, Morris SW, Pagano M et al. Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1. J Biol Chem 2007; 282: 15965-15972. (Pubitemid 47100379)
17. Bassermann F, von Klitzing C, Munch S, Bai RY, Kawaguchi H, Morris SW et al. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 2005; 122: 45-57. (Pubitemid 40977939)
18. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin Jr WG. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 2004; 428: 194-198. (Pubitemid 38374317)
19. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF(Skp2- Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 2004; 428: 190-193. (Pubitemid 38374316)
20. Benmaamar R, Pagano M. Involvement of the SCF complex in the control of Cdh1 degradation in S-phase. Cell Cycle 2005; 4: 1230-1232. (Pubitemid 41365394)
21. Guardavaccaro D, Pagano M. Stabilizers and destabilizers controlling cell cycle oscillators. Mol Cell 2006; 22: 1-4.
22. Kumagai A, Dunphy WG. Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol Cell 2000; 6: 839-849.
23. Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008; 20: 650-660.
24. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV et al. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003 2003/11/06/ 426: 87-91. (Pubitemid 37432546)
25. Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge SJ et al. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003; 17: 3062-3074. (Pubitemid 38040770)
26. Sadhu K, Reed SI, Richardson H, Russell P. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Proc Natl Acad Sci USA 1990; 87: 5139-5143.
27. Galaktionov K, Beach D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 1991; 67: 1181-1194. (Pubitemid 121001530)
28. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7: 495-507. (Pubitemid 46985396)
29. Nagata A, Igarashi M, Jinno S, Suto K, Okayama H. An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. New Biol 1991; 3: 959-968.
30. Lammer C, Wagerer S, Saffrich R, Mertens D, Ansorge W, Hoffmann I. The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J Cell Sci 1998; 111 ( Pt 16): 2445-2453. (Pubitemid 28434930)
31. Perdiguero E, Nebreda AR. Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle 2004; 3: 733-737. (Pubitemid 40187901)
32. Mailand N, Podtelejnikov AV, Groth A, Mann M, Bartek J, Lukas J. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J 2002; 21: 5911-5920. (Pubitemid 35315288)
33. Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J 1994; 13: 4302-4310. (Pubitemid 24295202)
34. Ray D, Terao Y, Nimbalkar D, Hirai H, Osmundson EC, Zou X et al. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res 2007; 67: 6605-6611. (Pubitemid 47105505)
35. Ferguson AM, White LS, Donovan PJ, Piwnica-Worms H. Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol Cell Biol 2005; 25: 2853-2860. (Pubitemid 40381646)
36. Busino L, Chiesa M, Draetta GF, Donzelli M. Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 2004; 23: 2050-2056. (Pubitemid 38496734)
37. Ray D, Terao Y, Fuhrken PG, Ma ZQ, DeMayo FJ, Christov K et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res 2007; 67: 984-991.
38. Lukas C, Sorensen CS, Kramer E, Santoni-Rugiu E, Lindeneg C, Peters JM et al. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 1999; 401: 815-818.
39. Sorensen CS, Lukas C, Kramer ER, Peters JM, Bartek J, Lukas J. A conserved cyclinbinding domain determines functional interplay between anaphase-promoting complex- Cdh1 and cyclin A-Cdk2 during cell cycle progression. Mol Cell Biol 2001; 21: 3692-3703. (Pubitemid 32466983)
40. Mitra J, Enders GH, Azizkhan-Clifford J, Lengel KL. Dual regulation of the anaphase promoting complex in human cells by cyclin A-Cdk2 and cyclin A-Cdk1 complexes. Cell Cycle 2006; 5: 661-666.
41. Di Fiore B, Pines J. Defining the role of Emi1 in the DNA replication-segregation cycle. Chromosoma 2008; 117: 333-338.
42. Miller JJ, Summers MK, Hansen DV, Nachury MV, Lehman NL, Loktev A et al. Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev 2006; 20: 2410-2420. (Pubitemid 44320389)
43. Rape M, Kirschner MW. Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature 2004; 432: 588-595. (Pubitemid 39626259)
44. Sudo T, Ota Y, Kotani S, Nakao M, Takami Y, Takeda S et al. Activation of Cdh1- dependent APC is required for G1 cell cycle arrest and DNA damage-induced G2 checkpoint in vertebrate cells. EMBO J 2001; 20: 6499-6508. (Pubitemid 33078722)
45. Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 2008; 134: 256-267. (Pubitemid 352010329)
46. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T et al. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci USA 2004; 101: 4419-4424. (Pubitemid 38437427)
47. Mamely I, van Vugt MA, Smits VA, Semple JI, Lemmens B, Perrakis A et al. Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Curr Biol 2006; 16: 1950-1955. (Pubitemid 44486756)
48. Mailand N, Bekker-Jensen S, Bartek J, Lukas J. Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol Cell 2006; 23: 307-318. (Pubitemid 44128852)
49. Peschiaroli A, Dorrello NV, Guardavaccaro D, Venere M, Halazonetis T, Sherman NE et al. SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol Cell 2006; 23: 319-329. (Pubitemid 44128849)
50. Garcia-Higuera I, Manchado E, Dubus P, Canamero M, Mendez J, Moreno S et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol 2008; 10: 802-811. (Pubitemid 351927709)
51. Skaar JR, Pagano M. Cdh1: a master G0/G1 regulator. Nat Cell Biol 2008; 10: 755-757. (Pubitemid 351927702)
52. Stegmeier F, Amon A. Closing mitosis: the functions of the Cdc14 phosphatase and its regulation. Annu Rev Genet 2004; 38: 203-232. (Pubitemid 40013728)
53. D'mours D, Amon A. At the interface between signaling and executing anaphase-Cdc14 and the FEAR network. Genes Dev 2004; 18: 2581-2595. (Pubitemid 39453097)
54. Sullivan M, Morgan DO. Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol 2007; 8: 894-903. (Pubitemid 47622563)
55. Lee J, Kim JA, Barbier V, Fotedar A, Fotedar R. DNA damage triggers p21WAF1- dependent Emi1 down-regulation that maintains G2 arrest. Mol Biol Cell 2009; 20: 1891-1902.
56. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008; 9: 759-769.
57. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia. Mutat Res 2009; 668: 11-19.
58. Kee Y, Kim JM, D'ndrea A. Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. Genes Dev 2009; 23: 555-560.
59. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000; 2: 672-676.
60. Visintin C, Tomson BN, Rahal R, Paulson J, Cohen M, Taunton J et al. APC/C-Cdh1- mediated degradation of the Polo kinase Cdc5 promotes the return of Cdc14 into the nucleolus. Genes Dev 2008; 22: 79-90.
61. Dehan E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN et al. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 2009; 33: 109-116.
62. Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB, Verma IM. Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci USA 2009; 106: 2629-2634.
63. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 2004; 1695: 189-207. (Pubitemid 39574973)
64. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-786. (Pubitemid 41721026)
65. Song L, Rape M. Reverse the curse-the role of deubiquitination in cell cycle control. Curr Opin Cell Biol 2008; 20: 156-163.
66. Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005; 17: 331-339. (Pubitemid 40193305)
67. Huang TT, Nijman SM, Mirchandani KD, Galardy PJ, Cohn MA, HaasWet al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol 2006; 8: 339-347.
68. Faustrup H, Bekker-Jensen S, Bartek J, Lukas J, Mailand N. USP7 counteracts SCFbetaTrCP- but not APCCdh1-mediated proteolysis of Claspin. J Cell Biol 2009; 184: 13-19.
69. Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006; 126: 529-542. (Pubitemid 44163600)
70. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004; 13: 879-886. (Pubitemid 38438482)
71. Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 2005; 18: 565-576. (Pubitemid 40726233)
72. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 2004; 36: 147-150. (Pubitemid 38174372)
73. Popov N, Herold S, Llamazares M, Schulein C, Eilers M. Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle 2007; 6: 2327-2331. (Pubitemid 350058681)
74. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007; 9: 765-774. (Pubitemid 47019463)
75. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4: 216-225. (Pubitemid 38337501)
76. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321-330.
77. Renner AG, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski A et al. Polo-like kinase 1 is over-expressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009; 114: 659-662.
78. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008; 17: 879-895. (Pubitemid 351864325)
79. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci 2009; 100: 24-28.
80. Cardozo T, Pagano M. Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes. BMC Biochem 2007; 8 (Suppl 1): S9.